CoA Therapeutics
Anna Wade, Ph.D., is Vice President of Business Development and Operations for CoA Therapeutics, where she is responsible for guiding corporate strategy and ensuring the smooth operation of the company. After spending two years as a strategy consultant at L.E.K. consulting, she joined the CoA Therapeutics team and returned to her scientific roots in oncology and neuroscience. Dr. Wade earned a Ph.D. in neuroscience from University College London and served as a post-doctoral researcher in neuro-oncology at the University of California, San Francisco.
CoA Therapeutics
CoA Therapeutics was founded in 2018 with the aim of harnessing advances in understanding of the CoA pathway to develop novel therapies for difficult to treat and rare genetic disorders.